← Research library

Cortexin administration due to improvement of cognitive and behavioral disorders in children and teenagers with epilepsy

Observational study · 2021

What was studied
86 children and adolescents with epilepsy
Main finding
In an 86-person pediatric epilepsy report, cognitive improvement was reported in 65% and no seizure aggravation in 95% during adjunctive Cortexin use.

Within the treated report; no untreated response proportion supplied

Reported findings and study design

In an 86-person pediatric epilepsy report, cognitive improvement was reported in 65% and no seizure aggravation in 95% during adjunctive Cortexin use.

86 children and adolescents aged 3–17 (41 girls, 45 boys); Cortexin alongside antiepileptic drugs.

Results · Primary-publication indexed abstract; no full-text table appraisal
MeasureResultComparison, timing and statistics
Cognitive improvement65%Within the treated report; no untreated response proportion supplied
No seizure aggravation95%This is not a seizure-remission rate
Baseline cognitive distribution72% had IQ 91–110; 24% described as mental deficiencyBaseline characteristics, not treatment response

The abstract does not give a controlled cognitive effect or seizure-worsening case descriptions. Adjunctive treatment and observational design limit attribution.

Source for these results ↗ · Reviewed 2026-11-01

Study limitations and source details

Study limitations

  • That observation is not proof of seizure safety; no randomized untreated comparator described.
  • Pediatric clinical findings do not establish enhancement or safety in healthy adults.

Source details

Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.

Sources checked

Citation

Uncontrolled human reportEnglish abstract

V Kalmykova G, Chefranova ZY, Rybnikova VF, Zubova KO. Cortexin administration due to improvement of cognitive and behavioral disorders in children and teenagers with epilepsy Zh Nevrol Psikhiatr Im S S Korsakova 121(3):127-131. PMID 33834730

Study source ↗ · DOI 10.17116/jnevro2021121031127 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards